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Abstract Liver diseases represent an important cause of
morbidity and mortality in the world. Death of hepatocytes
and other hepatic cell types is a characteristic feature of
several forms of liver injury such as cholestasis, viral
hepatitis, drug- or toxin-induced injury, and alcohol-
induced liver damage. Moreover, irrespectively of the
reason, liver injury seems to be facilitated by similar
immune effector mechanisms common to these various
liver diseases. Indeed, common immune effector mecha-
nisms may explain the high prevalence of cirrhosis and
cancer development in most forms of liver disease.
Improved understanding of the immune cell-mediated
mechanisms involved in hepatocyte cell death could be
beneficial for the development of common therapeutic
strategies against different forms of liver diseases. In this
review, we will discuss novel findings on the role of
different immune cells in liver disease and immune cell-
induced death executioner mechanisms involved in hepato-
cyte cell death.
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Introduction
The liver represents a vital organ of the gastrointestinal
system. Its main function is to take up nutrients, to store
them, and to release them on demand to other organs. It
occupies a key position between the gastrointestinal and
systemic venous circulations. One of its several functions is
to filter the blood coming from the gut through the portal
vein and from the systemic venous circulation through the
liver artery. Because of its anatomical link to the intestinal
tract and to the venous circulation, this organ is constantly
exposed to several external compounds, potential patho-
gens, and food-derived antigens entering the body via the
gut and drug metabolites, toxins, and tumor cells from the
blood system. Thus, similar to the gut, the liver has
developed, on one hand, a complex and particular immune
system able to mount a rapid immune response against
potentially dangerous pathogens without leading to damage
of the organ and, on the other hand, complex apoptosis
mechanisms of tissue cells, i.e., hepatocytes, to render them
less susceptible to immune cell-mediated damage. Despite
the constant exposure to low levels of gut-derived bacteria
and bacterial products, no signs of ongoing inflammation
are usually present in the liver under physiological
condition. This lack of response is, to some extent,
explained by very specific immunological properties of
the liver, which contribute to a certain degree to systemic
tolerance, as seen by graft survival, induction of systemic
tolerance to gut-derived antigen, and persistence of some
viral infections in the liver [1, 2]. As in the gastrointestinal
tract, the normal liver contains a large population of
resident immune cells that differ from those in the
peripheral blood. These cells include a large number of
natural killer (NK) cells, NK T cells, Kupffer cells, and
specific antigen-presenting cells. These specialized immune
cells play an essential role in both liver immune homeosta-
sis as well as in liver immunopathologies. For instance, NK
T cells and NK cells participate in the suppression of liver
metastases [3, 4]. Kupffer cells produce tumor necrosis
factor-α (TNFα) and interleukin (IL)-10 in response to
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physiological concentration of lipopolysaccharide (LPS)
[5–7].
The consequences of uncontrolled inflammatory immune
responses have been illustrated during the pathogenesis of
different liver diseases, such as viral hepatitis, alcoholic liver
disease, and autoimmune hepatitis. For instance, upon viral
infection of the liver virus-specific and bystander-activated T
cells not only kill virus-infected cells but also cause severe
damage to uninfected cells, leading to the development of
liver injury. The specific role of immune cells and their
effector mechanisms involved in different forms of liver injury
has been extensively studied but is still a matter of discussion.
NK cells, NK T cells, activated T cells, and Kupffer cells all
play an essential role in different forms of liver pathology.
Once activated, these immune cells express different tumor
necrosis factor (TNF) family members, i.e., Fas ligand (FasL;
CD95), TNFα, and tumor necrosis factor-related apoptosis-
inducing ligand (TRAIL), potentially able to participate to
hepatocyte cell death. Whether and how these cytotoxic
mediators collaborate in hepatocyte apoptosis is still not
sufficiently clear. One possibility could be that these media-
tors represent effector molecules of separate signaling path-
ways inducing hepatocyte cell death at different and
independent checkpoints. The other possibility could be that
these mediators represent effector molecules of the same
apoptosis signaling cascade. Crosstalk between these apopto-
sis pathways will be discussed later.
Besides a complex immune system, the liver parenchy-
mal cells, i.e., hepatocytes, have developed a peculiar and
complex cell death machinery to render them less suscep-
tible to potential dangerous signals. For instance, Fas
receptor-induced apoptosis has been extensively studied in
hepatocytes due to its critical dependence on the mitochon-
drial apoptosis pathway. In contrast to normal cells in
which Fas triggering directly induces the activation of
caspases and subsequently apoptosis (type I cells), hepato-
cytes require the amplification of the signal via the
mitochondria (type II cells). While many tumor cells are
type II cells, hepatocytes are probably the only known
representatives of primary cells of this amplification loop of
the Fas signaling pathways.
In this review, we will present an overview of the new
findings on the role of death executioner mechanisms
utilized by immune cells in liver disease. We will
emphasize mainly the role of FasL, TNFα, and TRAIL,
respectively, and how these cytotoxic mediators collaborate
in hepatocyte apoptosis in several forms of liver injury.
Role of immune cell in liver pathologies
Liver diseases are one of the most important causes of
morbidity and mortality worldwide. Several different
triggers have been implicated in the development of liver
disease. These include hepatitis B and C virus, toxic
compounds, alcohol abuse, and increase levels of free fatty
acid. One of the major and common clinical problems of all
of these forms of liver disease is the frequent development
of liver cirrhosis or liver cancer related to chronic
inflammation. Due to the limited availability of human
liver samples and the difficulties to experimentally manip-
ulate them, several animal models mimicking human liver
diseases have emerged. The predominantly used animal
models of liver disease are concanavalin A (ConA)-, LPS-,
alcohol-, and polyinosinic/polycytidylic acid (Poly I:C)-
induced liver injury, and transgenic mouse models for
hepatitis B and C virus. All of these models provide
evidences that activation of inflammatory responses
accounts for liver damage, as illustrated in Table 1. ConA,
a plant-derived lectin that activates T lymphocytes and NK
cells, has been widely exploited to induce acute liver injury
in mice in a dose of 10–20μg/g body weight [8]. In this
model of liver disease, injury can be efficiently prevented
by treating the mice with dexamethasone, an immunosup-
pressive steroid, indicating that liver disease is associated
with the activation of immune cells [8]. Searching for these
immune cell subsets responsible for ConA-induced liver
damage, it was demonstrated that NK T cell-deficient mice
(CD1d−/− and Vα14−/− mice) were resistant to this form of
liver disease, suggesting that uncontrolled activation of
these unconventional T cells, present in large numbers in
the liver, plays a central role in the development of liver
damage. However, not only NK T cells are essential in the
development of liver disease but also several other cell
subsets of the innate immune system, i.e., Kupffer cells,
neutrophils, and eosinophils, have been shown to partici-
pate in the development of ConA-induced liver damage [9–
12]. The exact mechanism how these different cell subsets
interplay with each other in the development of liver injury
is still not exactly known. Most probably, these immune
cells either directly participate in liver cell death via the
expression of apoptosis-related effector molecules, e.g.,
TNFα, FasL, and TRAIL, or are involved in the amplifi-
cation of the immune response via the release of proin-
flammatory mediators (e.g., interferon gamma (INFγ),
IL-12, IL-1, IL-18, and chemokines) [13–17]. As summa-
rized in Table 1, most of these cell populations not only
represent relevant players in ConA-induced liver damage
but also participate in the development of other forms of
liver injury. For instance, Kupffer cells have been reported
to be an essential initiator of pathologies in several hepatitis
models. In the liver, activated Kupffer cells represent one of
the major sources of proinflammatory cytokines, such as
TNFα and IL-1β. They constitutively express different toll-
like receptor (TLRs), such as TLR3 and TLR4, on the cell
surface and can be activated via the interaction of these
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receptors with their specific ligands Poly I:C and LPS,
respectively [18]. Endogenous LPS is normally present at
high concentrations in gram-negative bacteria colonizing
the colon. Since nanograms of LPS injected into the blood
stream can result in a vigorous inflammatory responses and,
as a consequence, in septic shock, the body has developed
strong defense mechanisms that tightly regulate the entry
and processing of LPS to the body. Strategically located
between the gastrointestinal tract and the portal blood flow,
the liver plays a crucial role in this process, not only by its
ability to clear LPS but also to respond vigorously to
increased amount of LPS via the activation of Kupffer cells
and the release of proinflammatory mediators and reactive
oxygen intermediates. Endogenous gut-derived bacterial
LPS has been indeed implicated as important cofactors in
the pathogenesis of several models of liver disease. In
alcohol- or carbon tetrachloride-induced liver injury, the
damage was reduced in germ-free mice or after oral
administration of antibiotics [19–21]. In contrast, additional
LPS aggravated liver damage induced by these different
hepatotoxic compounds [22]. In these models, the presence
of LPS was responsible for the activation of Kupffer cells
and, as a consequence, the release of TNFα. Accordingly,
inactivation of Kupffer cells with gadolinium chloride
decreases injury in alcohol-induced liver disease [23].
Thus, given their location and their characteristics, Kupffer
cells represent sentinel cells between the gastrointestinal
tract and the systemic circulation able to mount a rapid
immune response once a potential danger is entering the
blood stream.
NK cells are another important player in the pathology
of different liver diseases. This cell subset represents 20%
of the lymphocytes population in the liver and has been
considered a first line of defense against virus infection and
liver metastases. Many groups have yet described the
critical roles of NK cells in the pathogenesis of liver injury
models, among which, Poly I:C-induced liver injury was
the most useful for the understanding of the role of NK
cells. In this model, activation of TLR3 via Poly I:C
significantly induced accumulation and activation of NK
cell in the liver [24, 25]. This form of liver injury was
characterized by local spotty necrosis in the liver and only
slight elevation of transaminase activity in the serum, in
contrast to the massive necrotic lesions observed in ConA-
treated animals. When analyzing how NK T cells induced
liver damage, it was found that TRAIL, FasL, and perforin
synergize in inducing hepatocyte cell death.
Death receptors in liver pathology
The continuously growing family of structurally related
proteins of TNF family has received enormous scientific
attention due to their important role in the regulation of cell
activation, survival, death, and many other physiological and
pathological events. All members of this family act as ligands
and mediate their activity through cognate interaction with
their respective transmembrane receptors. The ligands, in-
cluding the prototypical members TNFα, FasL, and TRAIL,
have potent apoptosis-inducing activities in vivo and in vitro,
indicating an important role for these molecules in various
processes involving cellular suicide and cell-mediated cyto-
toxicity. The respective death receptors, interacting with these
ligands, are transmembrane proteins with three major func-
tional domains: an extracellular ligand-interacting domain, a
transmembrane domain, and an intracellular death domain,
which enable death receptors to initiate apoptosis signals.
These death receptors include Fas, TNFR-1, and TRAIL
receptors 1 and 2. Concerning the liver, there is growing
evidence demonstrating that apoptosis induced by the
interaction of the ligands of TNF family member with the
respective death receptors is a common feature in different
forms of liver injury. Hepatocytes express all death receptors
on their cell surface and can be activated by the respective
ligands, which are present on several different activated
immune cells [26].
Liver injury models Effector cells Effector molecules
ConA T cells (NK T cells) INFγ, TNFα, FasL, IL-4, TRAIL
Kupffer cells Superoxide anions, TNFα
Neutrophils
LPS/D-Gal Kupffer cells TNFα, chemokines
Poly I:C NK cells FasL, TRAIL
Alcohol NK T cells FasL, TNFα
Neutrophils Chemokines
Free fatty acid Kupffer cells TNFα, FasL
Paracetamol NK cells FasL, TNFα, TRAIL
Neutrophils TNFα
Table 1 Most important im-
mune effector cells and effector
molecules involved in different
forms of liver injury
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Fas receptor/ligand interaction in liver injury
Among the death receptors, presumably the FasL/Fas
system plays the most important pathogenic role in liver
injury. Under physiological condition, hepatocytes as well
as Kupffer cells, stellate cells, and endothelial cells express
the Fas receptor on their cell surface, whereas the respective
ligand, i.e., FasL, is normally expressed on NK cells and
NK T cells. A physiological role of the Fas receptor in the
liver was originally established in mice carrying natural
mutation in the Fas receptor gene (lpr) [27, 28]. With
increasing age, these mice develop liver hyperplasia
demonstrating the need of the Fas receptor in maintaining
tissue homeostasis [29]. Indeed, Fas-induced cell death
represents an important mechanism for the removal of
transformed hepatocytes, such as virus-infected cells or
cancer cells, via activated NK T cells and NK cells.
However, overactivation of the Fas receptor in the liver
has been shown to lead to tissue destruction and organ
failure. This has been well documented by massive
hepatocyte apoptosis in mice after injection of activating
anti-Fas antibodies or recombinant FasL [30, 31]. These
mice died already 2–4 h after activation of the Fas receptor.
Murine, as well as human hepatocytes, is, in fact, extremely
sensitive to Fas-induced apoptosis, in vitro and in vivo. The
intracellular mechanisms involved in this process will be
discussed in details later. This Fas-induced pathway of
hepatocyte death represents a common feature of several
different forms of liver damage. Cell death induced by
FasL/Fas interaction has been shown to play a central role
not only in T cell-mediated liver pathologies induced by
ConA and chronic viral hepatitis (e.g., hepatitis C) but also
in liver injuries induced by toxic agents, such as acetamin-
ophen overdose, alcohol, and cholestatic liver damage [32,
33]. Experiments using FasL-mutant mice (gld) or those
using Fas knockdown by siRNA in mice provided clear
evidence for a critical role of the Fas/FasL pathway in
ConA-induced liver injury [30, 31]. NK T cells expressing
FasL were directly involved in the induction of hepatocyte
apoptosis [34]. In humans, the role of FasL/Fas in the
development of liver injury upon hepatitis B and C
infection remains more enigmatic. In hepatitis C infection,
upregulation of Fas on hepatocytes and FasL on activated T
cells correlates with the severity of damage, and Fas
expression was significantly higher on infected hepatocytes
than on noninfected cells [35]. Fas expression could be
induced in hepatocytes either by virus-specific proteins or
by inflammatory cytokines such as IL-1β [36–39]. Acti-
vated cytotoxic T cells expressing FasL were then able to
induce apoptosis in virus-infected hepatocytes and also in
neighboring uninfected hepatocytes, leading to tissue
damage. On the other hand, it was demonstrated that the
hepatitis C virus could protect hepatocytes from Fas-
induced apoptosis by repressing the release of cytochrome c
from the mitochondria [40]. Therefore, hepatitis virus
proteins may both sensitize hepatocytes to Fas-induced
apoptosis and inhibit apoptosis as a possible mechanism for
viral immune escape and for maintaining persistent infection.
As mentioned earlier, FasL/Fas-mediated apoptosis plays
an important role not only in direct T cell-mediated liver
damage, such as during virus infections, but also in alcohol-,
cholestasis-, as well as acetaminophen-induced liver
damage [41]. Hepatocyte apoptosis has been reported to
be an important feature of alcoholic hepatitis, and the
number of apoptotic cells present in the affected liver
correlates with the severity of disease, as hepatocyte
apoptosis is enhanced in patients with high transaminase
activity in the serum [38]. Similarly, enhanced expression
of FasL and Fas has been observed in patients with
alcoholic liver disease, compared to control individuals
[42]. In cholestasis, elevated bile acid concentrations
within the liver promote the development of liver cirrhosis
and liver failure. Toxic bile acids induced hepatocytes
death in vitro as well as in vivo by a Fas-dependent
mechanism, and in agreement with these results, hepato-
cyte apoptosis was reduced in lpr and gld mice after bile
duct ligation [43]. Thus, although the starting trigger of
hepatocyte damage is completely different in these various
liver diseases, the Fas-induced apoptosis pathway may
represent a common apoptosis mechanism involved in
several forms of liver injury.
TNF receptor/ligand interactions in liver injury
In addition to the FasL/Fas pathway, TNFα in its soluble as
well as in its membrane-bound form has been demonstrated
to participate in different forms of liver damage, including
hepatitis, alcoholic liver injury, ischemia/reperfusion injury,
and toxic liver damage [44]. TNFα is a pleiotropic
proinflammatory cytokine produced in the liver mainly by
activated Kupffer cells and in reduced amounts also by NK
cells, endothelial cells, and stellate cells. TNFα can bind to
two distinct receptors: TNFR-1 and TNFR-2. Both recep-
tors are expressed on hepatocytes, although only TNFR-1
contains a so-called death domain and can directly execute
apoptotic pathways. TNFR-2, on the other hand, does not
contain a death domain, and its main function is to amplify
the effect of TNFR-1 in promoting both cell death and
inflammation [45]. In contrast to the Fas receptor, where the
interaction with FasL has been shown to predominantly
induce pro-apoptotic signals, activation of TNFR-1 induces
both prosurvival signal as well as pro-apoptotic signals.
Compared to Fas, TNFR signaling contains additional
elements: Recruitment of the TNFR-associated protein
(TRAF2) and receptor-interacting protein (RIP) leads to
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activation of NF-κB and transcriptional activation of
prosurvival genes (e.g., Bcl-xL, A1, XIAP, and cellular
FLICE-like inhibitory protein (cFLIP)). The fundamental
role of TNFR-1 in the transcriptional activation of these
prosurvival genes has been well documented in liver
regeneration after partial hepatectomy [46]. TNFR-1, but
not TNFR-2, plays an essential role in hepatocyte prolifer-
ation, via the activation of the NF-κB and STAT3 pathway
[47]. Apoptotic signaling, on the other hand, occurs
subsequently via the adaptor protein TNFR-associated
death domain, which activates a Fas-associated death
domain protein (FADD)/caspase 8-dependent pathway.
Although TNFR-2 does not contain a death domain, both
TNFR-1 and TNFR-2 were reported to collaborate in liver
damage. The cooperative signaling of both receptors in
liver disease has been attributed to the ability of the
intracellular domain of TNFR-2 to attract adaptor mole-
cules, such as TRAF2, thereby inhibiting TNFR-1-induced
activation of the anti-apoptotic NF-κB pathway and in turn
facilitating TNFR-1-induced activation of the pro-apoptotic
machinery [48]. In this situation, the prosurvival signaling
normally predominates. This is well demonstrated in
TNFα-mediated animal model of hepatitis, where inhibitors
of protein synthesis need to be used in order to unmask the
pro-apoptotic signals induced by TNFα [49]. In addition,
mice with a hepatocyte-specific deletion of either Iκ kinase
(IKK), IKKβ, or IKKγ are more sensitive to ConA- or
LPS-induced liver disease [50].
It is currently clear that not only NF-κB plays a central role
in the decision between hepatocyte survival and death but also
the Jun kinase (JNK) pathway [51]. The role of JNK in liver
disease has been investigated in several different models of
injury. Whereas transient and modest activation of JNK by
TNFα is associated with cellular survival, prolonged and
robust JNK activation contributes to hepatocyte cell death
[52–54]. Moreover, the level of JNK activation seems to be
controlled by NF-κB activation. In the absence of NF-κB
activation, TNFα constantly induces JNK activation. This
extended activation of JNK contributes to cell death, and
inhibition of JNK can rescue hepatocytes from TNFα-
induced apoptosis in the presence of inhibitor of protein
synthesis, such as actinomycin D [55, 56]. These results
indicate that JNK exerts its pro-apoptotic activity indepen-
dently of transcription. Similarly, pretreatment of mice with
JNK inhibitors rescued the animals from the development of
severe liver injury. Moreover, TNFα-induced activation of
JNK correlated with liver damage after injection of ConA,
and JNK inhibitors could block hepatocyte cell death
induced by ConA [57, 58]. In contrast to these observations,
it was recently demonstrated that JNK is critically required
for TNFα expression in hematopoietic cells and it is not
mandatory for TNFα-triggered hepatocyte cell death during
the development of liver damage [59].
The biological role of TNFα in liver disease is even
more complex because TNFα plays an essential role as
inflammatory cytokine in the activation and recruitment of
different immune cells involved in liver disease, such as
neutrophils, NK cells, and activated T cells, to the site of
inflammation. Moreover, TNFα also mediates caspase-
independent death via the formation of reactive oxygen
species. RIP-1 is recruited to TNFR-1 and activates Nox1
(reduced nicotinamide adenine dinucleotide phosphate
oxidase), leading to reactive oxygen species formation,
sustained activation of JNK, and, as a consequence,
hepatocyte cell death [60].
TRAIL signaling pathways
None of the apoptosis-inducing members of the TNF family
has received as much attention in tumor biology as TRAIL.
The reason for this strong interest is the fact that
recombinant TRAIL specifically induces apoptosis in a
broad range of tumor cells, while leaving normal non-
transformed cells mostly unaffected. This is particularly
important in the liver. Although under physiological
conditions hepatocytes express TRAIL-Rs on their cell
surface and the respective ligand, i.e., TRAIL, is normally
expressed on hepatic NK cells and NK T cells, non-
transformed hepatocytes seem not to be sensitive to TRAIL
cytotoxicity [61, 62]. This finding has been of outmost
interest since injection of recombinant TRAIL does not lead
to liver damage, whereas recombinant FasL results in
severe tissue destruction and even death [63, 64]. It has
thus been suggested that nontransformed cells and, in
particular, hepatocytes are not susceptible to TRAIL-
induced apoptosis, opening all possibilities for TRAIL-
based cancer therapy. In vitro as well as in vivo tumor
models confirmed this idea. For instance, TRAIL treatment
substantially inhibited growth of a variety of human
tumors, including breast and colon carcinomas, gliomas,
and multiple myelomas, in xenograft experiments in
immunodeficient mice [65–68]. Critically, TRAIL treat-
ment did not appear to have any side effects on normal
tissue cells, in particular, in the liver. Moreover, Takeda et
al. reported that TRAIL expressed on hepatic NK cells
plays a substantial role in suppressing tumor metastasis
without leading to hepatocyte damage [69]. They showed
that freshly isolated NK cells from the liver expressed cell
surface TRAIL, which was responsible for spontaneous
cytotoxicity against TRAIL-sensitive tumor cells in vitro.
Administration of neutralizing monoclonal antibodies
against TRAIL significantly increased experimental liver
metastases of several TRAIL-sensitive tumor cell lines [69].
These experiments indicate that TRAIL-mediated cytotox-
icity of tumor cells by liver NK cells is an important
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antitumor mechanism, responsible for effective immune
surveillance. Consequently, one would expect that lack of
TRAIL leads to a dramatic increase in tumor incidence.
Surprisingly, however, TRAIL-deficient mice develop
normally and do not show spontaneous tumor development,
as it has been observed in p53-deficient mice [70].
Nonetheless, endogenous TRAIL may still play an impor-
tant role in the regulation of cancer development, since
syngeneic renal cell carcinomas [71] and B cell lymphomas
[70] grow faster and induce significantly more liver
metastasis in TRAIL-deficient mice than in control animals.
Several groups have questioned the specificity of
TRAIL-induced cell death for tumor cells, and accumulat-
ing evidence suggests now that TRAIL-induced apoptosis
not only is limited to tumor cells but may also be induced in
primary cells. It is likely that this observation has been
missed previously since TRAIL sensitivity in primary cells
may be under stringent control and only be activated under
certain pathological conditions. For example, it was
demonstrated that TRAIL might be involved in several
forms of liver disease. Most notably, we and others
demonstrated that TRAIL participates in ConA-induced
liver disease ([72] and unpublished data). While these data
convincingly show reduced liver damage in TRAIL-
deficient mice, the question remains why injection of
recombinant TRAIL, in contrast to recombinant FasL, does
not cause any signs of hepatitis. NK cells constitutively
express TRAIL; however, cellular activation may result in
increased cell surface expression of transmembrane TRAIL
[16, 25], thus potentially promoting TRAIL-induced apo-
ptosis in hepatocytes. Activation of liver-homing NK T
cells and NK cells, however, also leads to a massive burst
in INFγ production. INFγ is known to enhance the
susceptibility of various cells to death receptor-induced
apoptosis. In particular, Fas-induced apoptosis in tumor
cells is amplified by pretreatment with INFγ. It is thus
possible that high level of INFγ may result in increased
susceptibility of hepatocytes to TRAIL-induced apoptosis
[73, 74]. This suggests that although administration of
recombinant TRAIL might be safe under physiological
conditions, any kind of inflammatory context, e.g., bacterial
or viral infections, with subsequent release of proinflam-
matory cytokines, may allow or enhance TRAIL-induced
hepatotoxicity. The role of TRAIL in the development of
liver injury has subsequently been confirmed in many
different types of liver disease, i.e., hepatitis B and C
infection, and cholestatic liver disease [25, 37, 63, 75, 76].
In accordance with these results, we recently demonstrated
that TRAIL participates also in acetaminophen-induced
liver disease (A. Badmann, N. Corazza, T. Brunner,
unpublished data). Although a lot of effort has been done
to understand how exactly TRAIL contributes to liver
damage, the precise molecular mechanism remains a matter
of debate. Sensitivity of hepatocytes to TRAIL-induced cell
death has been associated primarily with increased surface
expression of TRAIL-Rs on hepatocytes and TRAIL on
hepatocytes and NK cells. Hepatitis B virus infection of
human hepatocytes, as well as free fatty acid, has been
reported to induce the expression of TRAIL-R1 in
hepatocytes [77], targeting them to NK cell-mediated lysis.
Accordingly, TRAIL was increased in the serum of patient
with viral hepatitis, and viral infections in mice induced
TRAIL expression in the liver [78]. Since functional
surface expression of TRAIL has often been associated
with stimulation by cytokines, such as INFs, the upregula-
tion of TRAIL may be an important underlying reason for
the successful use of INFα as an approved treatment option
of patients chronically infected with hepatitis viruses. INFα
treatment may, on one hand, sensitize hepatocytes to
TRAIL-induced apoptosis [79] and, on the other hand, lead
to increased TRAIL expression in liver-homing lympho-
cytes [80]. Thus, upregulation of TRAIL and TRAIL-Rs on
hepatocytes and liver-homing lymphocytes could be an
important mechanism to selectively eliminate virally
infected hepatocytes. Recently, however, Malhi et al.
demonstrated that TRAIL is also an important mediator of
apoptosis in nonviral liver damage, such as free fatty acid-
induced liver disease [81]. They showed that oleic acid
induced upregulation of TRAIL-R2 on hepatocytes sensi-
tizing them to TRAIL cytotoxicity. Upregulation of TRAIL
and TRAIL-R, however, seems not to be the only
mechanism involved in the sensitization of hepatocytes to
TRAIL-induced cytotoxicity. It appears that sensitivity
toward TRAIL-induced apoptosis does not always correlate
with TRAIL receptor expression on target cells, but several
other intracellular factors may play an essential role in
rendering hepatocytes sensitive to TRAIL-induced cytotox-
icity. For instance, it was demonstrated that hepatitis C
virus infection sensitizes human hepatocytes to TRAIL-
induced apoptosis in a caspase 9-dependent manner [37,
82]. In line with these findings, other groups clearly
showed that the hepatitis B virus sensitizes hepatocytes to
TRAIL-induced apoptosis via the Bcl-2 protein Bax [83].
Taken together, all these results demonstrated that under
particular inflammatory conditions, TRAIL directly induces
hepatocyte apoptosis via interaction with its receptors.
Interestingly, the very analogous trigger of liver disease
has been demonstrated to sensitize hepatocytes not only to
TRAIL but also to FasL- as well as TNFα-induced
cytotoxicity. For instance, we and others demonstrated that
not only TRAIL but also other death ligands, such as TNFα
and FasL, are crucial for lectin-induced liver damage and
associated hepatitis. Indeed, it is well established that FasL
is expressed on activated liver T and NK T cells and
contributes to liver damage in experimental hepatitis. These
observations, together with the fact that injection of
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recombinant TRAIL does not cause any signs of hepatitis,
suggested to us that TRAIL signaling, rather than directly
inducing hepatocyte apoptosis, might cooperate with other
death signals in promoting hepatocyte cell death in vivo.
Thus, TRAIL may actually participate to hepatocyte
apoptosis by modulating apoptosis induced by other
triggers. In support of this notion, we found that recombi-
nant TRAIL alone does not induce apoptosis in isolated
murine hepatocytes; however, it strongly synergizes with
FasL in promoting hepatocyte cell death [63]. More
importantly, TRAIL-deficient mice were significantly more
resistant to liver damage and associated death in response to
injection of an agonistic anti-Fas antibody than control
animals. Similarly, we observed that TRAIL participates to
acetaminophen-induced liver damage (unpublished data). In
the presence of TRAIL, human hepatocytes were more
sensitive to acetaminophen-induced cell death, and TRAIL-
deficient mice were partially protected from the deleterious
effect of acetaminophen overdoses in vivo. This observa-
tion confirms the results obtained by others, who demon-
strated that deletion of NK cells, expressing TRAIL and
FasL, has a beneficial effect on the pathology of
acetaminophen-induced liver injury [84]. Taken together,
these findings suggest that different death-inducing signals
might collaborate in inducing hepatocyte apoptosis.
Modulation of the hepatocyte apoptosis
During the development of liver pathology, different
apoptosis-inducing mediators contribute to the development
of liver pathology and can influence the severity of the
disease. However, it is still a matter of debate whether these
apoptosis-inducing triggers, such as FasL, TRAIL, and
TNFα, represent mediators of independent parallel path-
ways or whether these diverse death triggers interact with
each other in order to amplify the apoptotic signal and to
mount a stronger and more efficient cell death response. A
complex control of hepatocyte apoptosis may be required to
regulate cell death of this physiologically so important cell
type. This would particularly make sense during the
development of liver immunopathologies. For instance,
during virus infection, activated immune cells, such as T
cells or NK cells, simultaneously expresses FasL, TRAIL,
and TNFα as well as perforin, which can cooperate in
target cell killing. Our own data suggest that these different
TNF family members do not initiate completely indepen-
dent parallel pathways, but rather collaborate together in
triggering hepatocyte apoptosis. In support to this notion,
we found that recombinant TRAIL alone does not induce
apoptosis in isolated murine hepatocytes; however, it
strongly synergizes with FasL in promoting hepatocyte cell
death [63].
Fas receptor-induced apoptosis has been extensively
studied in hepatocytes due to its critical interaction with
the mitochondrial apoptosis pathway. In contrast to normal
cells in which Fas triggering directly induces the activation
of caspases and subsequently apoptosis (type I cells),
hepatocytes require the amplification of the signal via the
mitochondria (type II cells). While many tumor cells are
type II cells, hepatocytes are probably the only known
representatives of this amplification loop of the Fas
signaling pathway. Triggering of Fas results only in limited
activation of caspase 8 in the death-inducing signaling
complex, unable to further activate the caspase amplifica-
tion cascade. Instead, caspase 8 must cleave the pro-
apoptotic Bcl-2 homolog Bid. The carboxyl-terminal
fragment of Bid (tBid) then translocates to the mitochon-
dria, where it mediates the release of cytochrome c and
other pro-apoptotic molecules. Consequently, Bid-deficient
mice are largely resistant to anti-Fas- and FasL-induced
liver damage and death [85, 86]. This finding clearly
demonstrates that in hepatocytes (and likely other type II
cells), the Fas signaling pathway cannot be efficiently
triggered in the absence of Bid, and thus, amplification of
the death receptor apoptosis pathway via the intrinsic
mitochondrial pathway is essential to induce hepatocyte
cell death via the FasL/Fas pathway.
This amplification loop via the mitochondrial apoptosis
pathway is not only restricted to FasL but represents also an
essential mechanism in TNFα-induced liver injury [49, 87].
Zhao et al. demonstrated that Bid-deficient mice are
partially protected from LPS/D-galactosamine-induced liver
injury proceeding via TNF/TNFR interactions [87]. Our
own results, however, suggest that the apoptosis signaling
cascade in this cell type may be even more complex and
involves additional apoptosis effector molecules. We have
observed that Fas-induced hepatocyte apoptosis and liver
damage are critically controlled by TRAIL, JNK, and the
pro-apoptotic Bcl-2 homolog Bim, as illustrated in Fig. 1
[63]. This additional control of apoptosis may add a further
safe guard for the protection of these cells from accidental
death induction and associated liver damage. TRAIL most
likely participates in hepatocyte apoptosis by modulating
the mitochondrial apoptosis pathway. While TRAIL alone
fails to induce apoptosis, we clearly demonstrated that
TRAIL modulated the FasL/Fas-induced apoptosis pathway
via the activation of mitogen-activated protein kinases, in
particular, activation of JNK resulting in the phosphoryla-
tion and activation of Bim. The precise mechanism how
TRAIL activates JNK in hepatocytes is still only partially
known. TRAIL-induced JNK activation occurs in a cell
type-specific manner. As reported in other cell types,
TRAIL can trigger JNK either through activation of
FADD/caspase 8 or through the adaptor molecules, TRAF2
and/or RIP.
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As described above, JNK has been implicated in various
forms of liver damage [53, 58, 59, 88]. We and others
demonstrated a critical role of TRAIL in the activation of
the JNK. For instance, we established that TRAIL activates
JNK and thereby amplifies the Fas pathway. Similarly,
Malhi et al. showed that free-fatty acids induce hepatocyte
lipoapoptosis in a TRAIL- and JNK-dependent manner [81,
89]. Yet, it remains to be defined which JNK isoform is
involved in TRAIL-induced modulation of hepatocyte
apoptosis. Hepatocytes like most cell types express two
JNK genes, jnk1 and jnk2. Their respective gene products,
JNK1 and JNK2, both consist of two alternative splicing
forms, p54 and p46 JNK. The p54 JNK isoform is
predominantly expressed by jnk2, and p46 JNK is primarily
a jnk1 product. Jnk1 and jnk2 null mice are both viable,
whereas the double knockout mouse is embryonically
lethal, suggesting that JNK1 and JNK2 have redundant
activities. Recent studies, however, demonstrated that the
products of jnk1 and jnk2 may have distinct functions. In
cultured hepatocytes, bile acid toxicity is mediated by
JNK2, whereas JNK1 is cytoprotective [89]. Similarly, it
was demonstrated that TNFα-induced liver disease was
JNK2-dependent [90]. Currently, it is unknown which JNK
isoform is involved in TRAIL-induced modulation of
hepatocyte cell death and how they regulate apoptosis.
JNK1 and JNK2 could modulate apoptosis in several ways,
including activation of pro-apoptotic Bcl-2 family proteins,
inactivation of anti-apoptotic Bcl-2 family proteins, induc-
tion of BH-3-only proteins, degradation of the anti-
apoptotic molecule cFLIP, or modulation of death receptor
expression. Searching for relevant JNK targets, we identi-
fied Bim as a critical JNK-regulated response modifier in
the TRAIL-initiated enhancement of hepatocyte apoptosis.
JNK phosphorylates BimEL and BimL in vitro and in vivo,
and in contrast to extracellular signal-related kinases 1 and
2-mediated phosphorylation and degradation by the proteo-
some, this leads to a dissociation of Bim from the
cytoskeleton and its activation [63, 91]. In agreement with
this proposed pathway, we observed that inhibition of JNK
and absence of TRAIL or Bim render mice largely resistant
to anti-Fas-induced liver damage [63]. We thus propose that
TRAIL-initiated activation of Bim represents a second
mitochondrial amplification loop, which further amplifies
Fas-induced caspase 8- and Bid-dependent apoptosis
signaling in hepatocytes.
TRAIL-mediated enhancement of the mitochondrial
pathway is also likely not restricted to Fas signaling in
type II cells, such as hepatocytes, but may further extend to
other triggers of the mitochondrial apoptosis pathway. In
support of this idea, we found that TRAIL can modulate
acetaminophen-induced liver damage in a JNK- and Bim-
dependent manner (unpublished data). Acetaminophen is a
commonly used analgesic and antipyretic agent. Although
considered safe at therapeutic doses, accidental or inten-
tional overdose frequently causes acute liver failure
characterized by centrilobular hepatic necrosis with high
morbidity and mortality. Despite substantial efforts, the
exact mechanisms of acetaminophen-induced liver cell
injury remain incompletely understood. There is a general
consensus that the P450 system-mediated formation of a
toxic electrophilic metabolite, most probably N-acetyl-p-
benzoquinone imine (NAPQI), is a prerequisite for
acetaminophen-induced hepatocytes injury. NAPQI is usu-
ally detoxified by glutathione in the liver. However,
acetaminophen overdose depletes hepatic glutathione
inasmuch as NAPQI can covalently bind to cellular proteins
leading to mitochondrial dysfunction. In experimental
animal models, the progression and severity of
acetaminophen-induced liver toxicity is not associated only
with the induction of the membrane permeability transition
and the collapse of mitochondrial membrane potential but
depends also on the interplay of other death-inducing
signals, both within and outside the hepatocytes. There is
a significant overlap between events normally associated
with apoptosis and acetaminophen-induced cell death. For
instance, mitochondrial events generally linked to apoptosis
have been observed in acetaminophen-induced hepatic cell
death, including the truncation of Bid, Bax translocation to
mitochondria, and release of cytochrome c [88, 92, 93]. In
agreement with the role of pro-apoptotic molecules in this
form of liver injury, we found that even in this type of liver
damage, TRAIL, through the activation of the JNK and
Bim axis, plays an essential role in acetaminophen-induced
liver injury. Thus, we believed that TRAIL-mediated
Fig. 1 Schematic model of the modulation of the Fas/FasL-induced
apoptosis pathway by the TRAIL–JNK–Bim axis. While TRAIL alone
fails to induce apoptosis, it triggers the activation of JNK. JNK leads
to the phosphorylation of Bim and to its release from the cytoskeleton.
Activation of Bim represents a second mitochondrial amplification
loop, which further amplifies caspase-8- and Bid-initiated apoptosis
signaling cascade in hepatocytes after Fas receptor ligation
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enhancement of the mitochondrial apoptosis pathway
represents a general amplification mechanism involved in
several models of hepatocyte cell death.
Conclusion
The question arises why TRAIL-induced signaling path-
ways in the liver are regulated in such a complex manner.
As mentioned above, liver-homing NK and NK T cells are
a rich source of TRAIL, and TRAIL-mediated cytotoxicity
also seems to play an important role in the immune cell-
mediated control of liver metastases. Clearly, if hepatocytes
would be intrinsically sensitive to TRAIL-induced apopto-
sis, the constitutive expression of TRAIL in liver NK and
NK T cells would be a constant threat and likely lead to
chronic liver destruction. Thus, it appears important that
under normal conditions, hepatocytes are insensitive to
TRAIL-induced apoptosis. The proposed amplification of
the mitochondrial apoptosis pathway by the TRAIL-JNK-
Bim axis may on the other hand ensure appropriate
hepatocyte apoptosis in response to other triggers and
under certain circumstances, e.g., when hepatocyte apopto-
sis is needed for the protection of the host. Of particular
interest in this regard is the fact that viral infections render
hepatocytes sensitive to TRAIL-induced apoptosis. Thus,
TRAIL may represent a safeguard for the liver allowing the
elimination of infected or transformed cells while sparing
normal liver cells required for the vital functions of this
important organ.
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